1361031-17-5

Basic information

• Product Name: ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate
• Synonyms: ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate
• CAS NO: 1361031-17-5
• Molecular Weight: 286.69
• Mol File: 1361031-17-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate(1361031-17-5)
• EPA Substance Registry System: ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate(1361031-17-5)

Safety Data

• Hazardous Substances Data: 1361031-17-5(Hazardous Substances Data)

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1361031-38-0 ethyl 4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylate 
• 636568-08-6 ethyl 1-(4-fluorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylate 
• 1361031-37-9 4-(2-dimethylaminoethyl)-1-(4-fluorophenyl)pyrazole-3-carboxylic acid 
• 1361030-62-7 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 
• 1361031-18-6 ethyl 4-ethoxy-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylate 
• 1172231-06-9 4-ethoxy-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylic acid 
• 1361031-19-7 4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride 
• 1361030-42-3 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide 

Relevant articles and documents

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.